Dermata Therapeutics, Inc.
DRMA
$1.21
-$0.02-1.63%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.97M | 5.33M | 4.84M | 4.48M | 4.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.60M | 7.36M | 7.77M | 9.07M | 10.54M |
| Operating Income | -8.60M | -7.36M | -7.77M | -9.07M | -10.54M |
| Income Before Tax | -8.37M | -7.10M | -7.56M | -8.85M | -10.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.37 | -7.10 | -7.56 | -8.85 | -10.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.37M | -7.10M | -7.56M | -8.85M | -10.33M |
| EBIT | -8.60M | -7.36M | -7.77M | -9.07M | -10.54M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4.51 | -5.43 | -9.42 | -16.94 | -35.71 |
| Normalized Basic EPS | -2.82 | -3.39 | -5.89 | -10.59 | -22.32 |
| EPS Diluted | -4.51 | -5.43 | -9.42 | -16.94 | -35.71 |
| Normalized Diluted EPS | -2.82 | -3.39 | -5.89 | -10.59 | -22.32 |
| Average Basic Shares Outstanding | 10.04M | 7.04M | 3.70M | 2.91M | 2.04M |
| Average Diluted Shares Outstanding | 10.04M | 7.04M | 3.70M | 2.91M | 2.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |